Immunocore

Historical price data

Immunocore's mission is to pioneer and deliver transformative immunomodulating medicines for cancer, infectious diseases, and autoimmune diseases. Its defining achievement is the 2022 FDA approval of KIMMTRAK (tebentafusp), the world's first TCR therapy, which validates its core ImmTAX platform technology. The company's strategy is to leverage this validated, modular platform to build a broad pipeline of bispecific TCR therapies, controlling value from discovery through commercialization. With a strong leadership team and a first-mover advantage in TCR therapeutics, Immunocore is positioned as a leader in next-generation immunotherapy.

The proprietary ImmTAX (Immune Mobilizing Monoclonal TCRs Against X disease) platform is a modular, bispecific T cell receptor technology designed to recognize intracellular disease-associated peptides presented on HLA molecules and redirect polyclonal T cells for targeted cell killing (ImmTAC/ImmTAV) or depletion (ImmTAAI).